The Peptide Synthesis Facility provides peptides (short segments of linked amino acids) for research on and the development of new agents for male and female contraception and other reproductive health applications. The facility synthesizes peptides that cannot be obtained from commercial sources. It is funded through a contract with the NICHD Contraceptive Discovery and Development Branch (CDDB) (formerly the Contraception and Reproductive Health (CRH) Branch).
The facility is capable of synthesizing compounds required for a variety of research uses, including animal model and other preclinical research, clinical research, and studies of pharmacokinetics and metabolism.
The facility provides Good Manufacturing Practice API peptides to qualified clinical and preclinical investigators.
The Peptide Synthesis Facility produces new peptides for evaluation by the Biological Testing Facility and for investigators affiliated with the CDDB-funded Contraceptive Development Research Center Program, among others.
Specific types of peptides produced by the facility include (but are not limited to) the following:
- Acyline. The facility produces this potent gonadotropin-releasing hormone (GnRH) antagonist in both preclinical and clinical formulations. Acyline produced at the facility has been used in CDDB-funded male contraceptive studies, studies of polycystic ovary syndrome, and research on other topics.
- Metastin. This compound stimulates GnRH and luteinizing hormone secretion. The facility produced this peptide for a translational research project approved by the NIH Rapid Access to Interventional Development (RAID) program, which was recently reconfigured as the Bridging Interventional Development Gaps (BrIDGs) program. The BrIDGs program, housed within the NIH National Center for Advancing Translational Sciences (NCATS), makes available critical preclinical resources needed for the development of new therapeutic agents.